Furthermore, combining the FAP-specific CAR T cells for stroma targeting with tumor-associated antigen (TAA)-redirected T cells (such as EphA2-CAR T) strengthened the antitumor activity of tumor-targeting T cells [79]. The gene discussed is FAP; the disease is neoplasm.